Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenet Genomics. 2013 Oct;23(10):558-62. doi: 10.1097/FPC.0b013e328364eb92.

Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.

Author information

aDepartment of Cardiology, Daejeon St. Mary's Hospital bDepartment of Cardiology, Yeouido St. Mary's Hospital cDepartment of Cardiology, Uijeongbu St. Mary's Hospital dDepartment of Cardiology, Seoul St. Mary's Hospital eDepartment of Cardiology, Incheon St. Mary's Hospital fDepartment of Cardiology, St. Vincent's Hospital gDepartment of Cardiology, St. Paul's Hospital hDepartment of Cardiology, Bucheon St. Mary's Hospital, The Catholic University of Korea iDepartment of Pharmacology, PharmacoGenomics Research Center, College of Medicine jDepartment of Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan, Korea.


The impact of the CYP2C19*17 polymorphism on the clinical outcome in Asians undergoing percutaneous coronary intervention (PCI) is unknown. We sought to assess the long-term impact of CYP2C19*17 on the risk for adverse clinical events in 2188 Korean patients taking clopidogrel after PCI. The prevalence of the CYP2C19*17 allele [*wt/*17: 2.4% (n = 53), *17/*17: 0%] was very low. The 2-year cumulative event rates for bleeding [*wt/*17 vs. *wt/*wt: 2 vs. 2.3%; adjusted hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.16-9.45], stent thrombosis (2 vs. 1.1%; HR, 3.98; 95% CI, 0.49-31.6) or composite of any death, and myocardial infarction or stroke (5.4 vs. 7.1%; HR, 1.37; 95% CI, 0.32-5.73) did not differ on the basis of the presence of CYP2C19*17. In conclusion, in our study population of Asian patients, the CYP2C19*17 polymorphism was not associated with adverse clinical outcomes after PCI because of its low prevalence, the rarity of homozygotes, and the relatively low rate of adverse clinical events.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center